Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy.

Persano M, Nollino L, Sambataro M, Rigato M, Negro I, Marchetto S, Paccagnella A

European review for medical and pharmacological sciences1 Jan 2021Cited by 19 (Europe PMC)

PMID33577047DOI10.26355/eurrev_202101_24661PepBankPUB-33577047

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes switched from multiple daily insulin injections, HbA1c was lower after 6 months on the degludec/liraglutide combination (8.4% versus 7.4%).
In plain wordsIn adults with type 2 diabetes, blood sugar control (HbA1c) improved after 6 months on an insulin and liraglutide combination product.
Peptide
Liraglutide
Outcome
DecreaseHbA1c at 6 months
Study
n: not reported in source
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c
8.4%
baseline
HbA1c
7.4%
6 months
Source sentences
Summary
HbA1c (8.4 vs. 7.4%; p<0.0001) and body weight (94.1 vs. 93 kg; p<0.0001) were significantly lower after 6 months for patients on the degludec/liraglutide combination.
1 context sentence(design, population, supporting numbers)
Summary · context
This observational, prospective and non-randomized trial enrolled type 2 DM patients referred to our outpatient clinic between January 2019 and December 2019, who were shifted from multiple daily-dose insulin injection therapy to degludec/liraglutide combination as per the physician's decision.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3357704701
02HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes switched from multiple daily insulin injections, body weight was lower after 6 months on the degludec/liraglutide combination (94.1 kg versus 93 kg).
In plain wordsIn adults with type 2 diabetes, body weight was slightly lower after 6 months on an insulin and liraglutide combination product.
Peptide
Liraglutide
Outcome
DecreaseBody weight at 6 months
Study
n: not reported in source
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Measurements
body weight
94.1 kg
baseline
body weight
93 kg
6 months
Source sentences
Summary
HbA1c (8.4 vs. 7.4%; p<0.0001) and body weight (94.1 vs. 93 kg; p<0.0001) were significantly lower after 6 months for patients on the degludec/liraglutide combination.
1 context sentence(design, population, supporting numbers)
Summary · context
This observational, prospective and non-randomized trial enrolled type 2 DM patients referred to our outpatient clinic between January 2019 and December 2019, who were shifted from multiple daily-dose insulin injection therapy to degludec/liraglutide combination as per the physician's decision.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3357704702
03HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes switched from multiple daily insulin injections, fasting glycemia was lower on the degludec/liraglutide combination (159 versus 125 mg/dl).
In plain wordsIn adults with type 2 diabetes, fasting blood sugar was lower after 6 months on an insulin and liraglutide combination product.
Peptide
Liraglutide
Outcome
DecreaseFasting glycemia at 6 months
Study
n: not reported in source
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Measurements
fasting glycemia
159 mg/dl
baseline
fasting glycemia
125 mg/dl
6 months
Source sentences
Summary
A similar trend was observed in fasting glycemia levels (159 vs. 125 mg/dl; p<0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
This observational, prospective and non-randomized trial enrolled type 2 DM patients referred to our outpatient clinic between January 2019 and December 2019, who were shifted from multiple daily-dose insulin injection therapy to degludec/liraglutide combination as per the physician's decision.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3357704703
04HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes, DTSQ scores were higher after 6 months on the degludec/liraglutide combination (mean 27 versus 20).
In plain wordsIn adults with type 2 diabetes, satisfaction with treatment was higher after 6 months on an insulin and liraglutide combination product.
Peptide
Liraglutide
Outcome
IncreaseTreatment satisfaction (DTSQ score)
Study
n: not reported in source
Analysis
Secondary
Outcome group
Quality of life · Whole body
Measurements
DTSQ mean score
27
6 months
DTSQ mean score
20
baseline
Source sentences
Summary
In addition, higher scores in the DTSQ were registered after 6 months on degludec/liraglutide (mean score: 27 vs. 20; p<0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
This observational, prospective and non-randomized trial enrolled type 2 DM patients referred to our outpatient clinic between January 2019 and December 2019, who were shifted from multiple daily-dose insulin injection therapy to degludec/liraglutide combination as per the physician's decision.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3357704705
05HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes, total daily insulin units were reduced on the degludec/liraglutide combination while glycemic control improved.
In plain wordsIn adults with type 2 diabetes, the insulin dose fell while blood sugar control improved on an insulin and liraglutide combination product.
Peptide
Liraglutide
Outcome
DecreaseTotal daily insulin dose
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
An improved glycemic control was achieved with degludec/liraglutide despite a reduction in total daily insulin units (42 U at 6 months vs. 22 U at baseline; p<0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
This observational, prospective and non-randomized trial enrolled type 2 DM patients referred to our outpatient clinic between January 2019 and December 2019, who were shifted from multiple daily-dose insulin injection therapy to degludec/liraglutide combination as per the physician's decision.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3357704704
06HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes, the degludec/liraglutide combination was less costly per patient per day than basal-bolus therapy.
In plain wordsIn adults with type 2 diabetes, an insulin and liraglutide combination product cost less per day than multiple daily insulin injections.
Peptide
Liraglutide
Outcome
DecreasePer-patient daily cost compared with basal-bolus therapy
Study
n: not reported in source
Comparator
Basal-bolus insulin therapy
Outcome group
Healthcare costs and utilization · Whole body
Source sentences
Summary
The combination therapy also proved more convenient than basal-bolus therapy in terms of costs, with an average per-patient cost difference of €-0.41±0.59/die (p<0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
This observational, prospective and non-randomized trial enrolled type 2 DM patients referred to our outpatient clinic between January 2019 and December 2019, who were shifted from multiple daily-dose insulin injection therapy to degludec/liraglutide combination as per the physician's decision.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3357704706

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.